Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

Investors may react cautiously to news that PPLPHARMA's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 56.655033
debtToEquity 60.533000
earningsGrowth -0.625000
revenueGrowth 0.125000
grossMargins 0.597880
operatingMargins 0.063940
trailingEps 0.340000
forwardEps 0.000000

PPLPHARMA's high forward PE ratio indicates potential overvaluation, which could restrict future price growth and increase the risk of a correction. It's crucial to consider this metric in tandem with other fundamental data to fully assess the stock's outlook.
PPLPHARMA's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
Piramal Pharma Limited's negative gross and operating margins indicate that the company is currently unprofitable at both the production and operational levels. This suggests significant challenges in managing costs and generating revenue, which could impact its overall financial health.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA



Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


Analysts' buy bias for PPLPHARMA signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to PPLPHARMA, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.